Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | PLG | P00747 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
| ▸ | PLAT | P00750 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | KLK1 | P06870 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31180930 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL29121938 | 0.98 | ALDH1A1 (0.52) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 | |
| SCHEMBL4074869 | 0.83 | ALDH1A1 (0.54) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 | |
| SCHEMBL29405526 | 0.77 | CTDSP1 (0.63) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 | |
| SCHEMBL29498396 | 0.77 | CTDSP1 (0.63) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 | |
| SCHEMBL729842 | 0.77 | CTDSP1 (0.63) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 | |
| SCHEMBL6562541 | 0.77 | CYP2A6 (0.52) | ALDH1A1HPGDTSHRHSD17B10PLG | |
| SCHEMBL30366448 | 0.77 | CYP2A6 (0.52) | ALDH1A1HPGDTSHRHSD17B10PLG | |
| SCHEMBL29351158 | 0.76 | ALDH1A1 (0.62) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 | |
| SCHEMBL5545202 | 0.76 | ALDH1A1 (0.62) | ALDH1A1HPGDCYP3A4TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240174650-A1 | 8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LONGIVITRON (SUZHOU) BIOTECHNOLOGY CO., LTD (CN) | 2024-05-30 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| CN-1653062-A | (imidazol-1-yl-methyl)-pyridazine as NMDA receptor blocker | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | CN | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| US-5132421-A | 2-naphthyl-carbapenem intermediates | MERCK & CO., INC. (US) | 1992-07-21 | — | — | US | disclosed |
| EP-0466254-A1 | 2-naphthyl-carbapenems | MERCK & CO. INC. (US) | 1992-01-15 | — | — | EP | disclosed |
| US-5032587-A | Antibiotics, carbapenicillins | MERCK & CO., INC. (US) | 1991-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885CYP3A4 195/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885CYP3A4 195/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885CYP3A4 195/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | ALDH1A1 1532/4885HPGD 785/4885CYP3A4 630/4885 |
| US-20240174650-A1 | 8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SIRT2, SIRT1, SIRT7 | ALDH1A1 1100/4885HPGD 560/4885CYP3A4 1635/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885CYP3A4 195/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885CYP3A4 195/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | ALDH1A1 1634/4885HPGD 1683/4885CYP3A4 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.